• ChemFaces is a professional high-purity natural products manufacturer.
  • Product Intended Use
  • 1. Reference standards
  • 2. Pharmacological research
  • 3. Inhibitors
  • Home
  • Natural Products
  • Bioactive
  • Screening Libraries
  • Hot Products
  • Plant Catalog
  • Customer Support
  • Product Use Citation
  • About Us
  • Contact Us
  • Natural Products
    Glycoursodeoxycholic acid
    Glycoursodeoxycholic acid
    Information
    CAS No. 64480-66-6 Price $100 / 20mg
    Catalog No.CFN89075Purity>=98%
    Molecular Weight449.63Type of CompoundSteroids
    FormulaC26H43NO5Physical DescriptionPowder
    Download     COA    MSDSSimilar structuralComparison (Web)
    How to Order
    Orders via your E-mail:

    1. Product number / Name / CAS No.
    2. Delivery address
    3. Ordering/billing address
    4. Contact information
    Sent to Email: info@chemfaces.com
    Contact Us
    Order & Inquiry & Tech Support

    Tel: (0086)-27-84237683
    Fax: (0086)-27-84254680
    E-mail: manager@chemfaces.com
    Address: No. 83, CheCheng Rd., WETDZ, Wuhan, Hubei 430056, PRC
    Delivery time
    Delivery & Payment method

    1. Usually delivery time: Next day delivery by 9:00 a.m. Order now

    2. We accept: Wire transfer & Credit card & Paypal & Western Union
    * Packaging according to customer requirements(5mg, 10mg, 20mg and more). We shipped via FedEx, DHL, UPS, EMS and others courier.
    Our products had been exported to the following research institutions and universities, And still growing.
  • Mahidol University (Thailand)
  • Universitas islam negeri Jakarta (Indonesia)
  • Universidad Veracuzana (Mexico)
  • University of Illinois (USA)
  • VIB Department of Plant Systems ... (Belgium)
  • University of Bordeaux (France)
  • Universiti Kebangsaan Malaysia (Malaysia)
  • Shanghai Institute of Biochemist... (China)
  • Seoul National University of Sci... (Korea)
  • Universidad de Antioquia (Colombia)
  • Auburn University (USA)
  • More...
  • Package
    Featured Products
    Sibiricaxanthone B

    Catalog No: CFN90644
    CAS No: 241125-81-5
    Price: $288/20mg
    Quercetin-3-gentiobioside

    Catalog No: CFN93585
    CAS No: 7431-83-6
    Price: $298/10mg
    Xanthohumol

    Catalog No: CFN98958
    CAS No: 569-83-5
    Price: $60/20mg
    3-O-Caffeoylquinic acid methyl ester

    Catalog No: CFN92573
    CAS No: 123483-19-2
    Price: $198/10mg
    Nodakenin

    Catalog No: CFN90232
    CAS No: 495-31-8
    Price: $138/20mg
    Biological Activity
    Description: 1. Glycoursodeoxycholic acid shows protective effects in Barrett's esophagus cells by inhibiting oxidative stress.
    2. Glycoursodeoxycholic acid and interleukin-10 modulate inflammation and cell survival, they may have potential benefits in reducing UCB-induced astrocyte immunostimulation and death.
    3. Glycoursodeoxycholic acid reduces matrix metalloproteinase-9 and caspase-9 activation in a cellular model of superoxide dismutase-1 neurodegeneration.
    Targets: TNF-α | IL Receptor | SOD | MMP(e.g.TIMP) | Caspase
    Glycoursodeoxycholic acid Description
    Source: The metabolites of ursodeoxycholic acid.
    Solvent: Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.
    Storage: Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).

    Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

    Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com

    After receiving: The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
    Recent ChemFaces New Products and Compounds
    Scopolin

    Catalog No: CFN98887
    CAS No: 531-44-2
    Price: $168/20mg
    Isokaempferide

    Catalog No: CFN93002
    CAS No: 1592-70-7
    Price: $368/5mg
    Ganoderic acid G

    Catalog No: CFN90801
    CAS No: 98665-22-6
    Price: $463/10mg
    Arteannuin B

    Catalog No: CFN98807
    CAS No: 50906-56-4
    Price: $228/20mg
    Tectoruside

    Catalog No: CFN95051
    CAS No: 38784-73-5
    Price: $288/20mg
    Licoricidin

    Catalog No: CFN96389
    CAS No: 30508-27-1
    Price: $388/5mg
    2''-O-acetylsaikosaponin A

    Catalog No: CFN95085
    CAS No: 102934-42-9
    Price: $318/5mg
    6-O-(E)-Caffeoylglucopyranose

    Catalog No: CFN95105
    CAS No: 209797-79-5
    Price: $298/5mg
    Recently, ChemFaces products have been cited in many studies from excellent and top scientific journals

    Cell. 2018 Jan 11;172(1-2):249-261.e12.
    doi: 10.1016/j.cell.2017.12.019.

    PMID: 29328914

    Mol Cell. 2017 Nov 16;68(4):673-685.e6.
    doi: 10.1016/j.molcel.2017.10.022.

    PMID: 29149595

    Scientific Reports 2017 Dec 11;7(1):17332.
    doi: 10.1038/s41598-017-17427-6.

    PMID: 29230013

    Molecules. 2017 Oct 27;22(11). pii: E1829.
    doi: 10.3390/molecules22111829.

    PMID: 29077044

    J Cell Biochem. 2018 Feb;119(2):2231-2239.
    doi: 10.1002/jcb.26385.

    PMID: 28857247

    Phytomedicine. 2018 Feb 1;40:37-47.
    doi: 10.1016/j.phymed.2017.12.030.

    PMID: 29496173
    Calculate Dilution Ratios(Only for Reference)
    1 mg 5 mg 10 mg 20 mg 25 mg
    1 mM 2.2241 mL 11.1203 mL 22.2405 mL 44.481 mL 55.6013 mL
    5 mM 0.4448 mL 2.2241 mL 4.4481 mL 8.8962 mL 11.1203 mL
    10 mM 0.2224 mL 1.112 mL 2.2241 mL 4.4481 mL 5.5601 mL
    50 mM 0.0445 mL 0.2224 mL 0.4448 mL 0.8896 mL 1.112 mL
    100 mM 0.0222 mL 0.1112 mL 0.2224 mL 0.4448 mL 0.556 mL
    * Note: If you are in the process of experiment, it's need to make the dilution ratios of the samples. The dilution data of the sheet for your reference. Normally, it's can get a better solubility within lower of Concentrations.
    Glycoursodeoxycholic acid References Information
    Citation [1]

    Dis Esophagus. 2010 Feb;23(2):83-93.

    Protective effects of glycoursodeoxycholic acid in Barrett's esophagus cells[Pubmed: 19549210 ]
    DNA damage and oxidative stress were significantly increased, while thiol levels were decreased in BE cells treated with pH 4 and bile acid cocktail compared with cells treated with pH 4 alone or untreated cells. Bile acids and low pH also significantly decreased cell proliferation. Expression of the antioxidant enzymes, MnSOD and CuZnSOD, was elevated in the cells treated with bile acids and low pH. When Glycoursodeoxycholic acid (GUDCA)was included in the medium, all these effects of pH 4 and bile acids were markedly reduced. In conclusion, treatment of BE cells with acidified medium and a bile acid cocktail at physiologically relevant concentrations induces DNA damage, cytotoxicity, and ROS. The cytoprotective bile acid, GUDCA, inhibits these deleterious effects by inhibiting oxidative stress.
    Citation [2]

    J Neuropathol Exp Neurol. 2007 Sep;66(9):789-98.

    Glycoursodeoxycholic acid and interleukin-10 modulate the reactivity of rat cortical astrocytes to unconjugated bilirubin.[Pubmed: 17805009]
    The pathogenesis of bilirubin encephalopathy seems to result from accumulation of unconjugated bilirubin (UCB) within the brain. We have recently demonstrated that UCB causes astroglial release of proinflammatory cytokines and glutamate, as well as cell death. The bile acid Glycoursodeoxycholic acid (GUDCA) and the anti-inflammatory cytokine interleukin (IL)-10 have been reported to modulate inflammation and cell survival. In this study we investigated the effect of these therapeutic agents on the astroglial response to UCB. Only GUDCA prevented UCB-induced astroglial death. The secretion of tumor necrosis factor-alpha (TNF-alpha) and IL-1beta elicited by UCB in astrocytes was reduced in the presence of GUDCA and IL-10, whereas the suppression of IL-6 was only counteracted by GUDCA. Neither GUDCA nor IL-10 modulated the accumulation of extracellular glutamate. Additionally, IL-10 markedly inhibited UCB-induced nuclear factor-kappaB nuclear translocation and cytokine mRNA expression, whereas GUDCA only prevented TNF-alpha mRNA expression. Moreover, GUDCA inhibited TNF-alpha- and IL-1beta-converting enzymes, preventing the maturation of these cytokines and their consequent release. Collectively, this study shows that IL-10 action is restricted to UCB-induced release of TNF-alpha and IL-1beta from the astrocytes, whereas GUDCA presents a more ubiquitous action on the astroglial reactivity to UCB. Hence, GUDCA may have potential benefits over an IL-10 therapeutic approach in reducing UCB-induced astrocyte immunostimulation and death.
    Citation [3]

    Mol Neurobiol. 2015;51(3):864-77.

    Glycoursodeoxycholic acid reduces matrix metalloproteinase-9 and caspase-9 activation in a cellular model of superoxide dismutase-1 neurodegeneration.[Pubmed: 24848512 ]
    We explored the mechanisms associated with superoxide dismutase-1 (SOD1) accumulation and MN degeneration in NSC-34/hSOD1(G93A) cells differentiated for 4 days in vitro (DIV). We examined GUDCA(Glycoursodeoxycholic acid) efficacy in preventing such pathological events and in restoring MN functionality by incubating cells with 50 μM GUDCA at 0 DIV and at 2 DIV, respectively. Increased cytosolic SOD1 inclusions were observed in 4 DIV NSC-34/hSOD1(G93A) cells together with decreased mitochondria viability (1.2-fold, p < 0.01), caspase-9 activation (1.8-fold, p < 0.05), and apoptosis (2.1-fold, p < 0.01). GUDCA exerted preventive effects (p < 0.05) while also reduced caspase-9 levels when added at 2 DIV (p < 0.05). ATP depletion (2-fold, p < 0.05), increased nitrites (1.6-fold, p < 0.05) and metalloproteinase-9 (MMP-9) activation (1.8-fold, p < 0.05), but no changes in MMP-2, were observed in the extracellular media of 4 DIV NSC-34/hSOD1(G93A) cells. GUDCA inhibited nitrite production (p < 0.05) while simultaneously prevented and reverted MMP-9 activation (p < 0.05), but not ATP depletion. Data highlight caspase-9 and MMP-9 activation as key pathomechanisms in ALS and GUDCA as a promising therapeutic strategy for slowing disease onset and progression.